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Abstract Skeletal muscle atrophy and fatty infiltration
develop after tendon tearing. The extent of atrophy serves
as one prognostic factor for the outcome of surgical repair
of rotator cuff tendon tears. We asked whether mRNA of
genes involved in regulation of degradative processes
leading to muscle atrophy, ie, FOXOs, MSTN, calpains,
cathepsins, and transcripts of the ubiquitin-proteasome
pathway, are overexpressed in the supraspinatus muscle in
patients with and without rotator cuff tears. We evaluated
biopsy specimens collected during surgery of 53 consecu-
tive patients with different sizes of rotator cuff tendon tears
and six without tears. The levels of corresponding gene
transcripts in total RNA extracts were assessed by semi-
quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) analysis. Supraspinatus muscle atrophy
was assessed by MRI. The area of muscle tissue (or atro-
phy), decreased (increased) with increasing tendon tear
size. The transcripts of CAPN1, UBE2B, and UBE3A were
upregulated more than twofold in massive rotator cuff tears
as opposed to smaller tears or patients without tears. These
atrophy gene products may be involved in cellular pro-
cesses that impair functional recovery of affected muscles
after surgical rotator cuff repair. However, the damaging
effects of gene products in their respective proteolytic
processes on muscle structures and proteins remains to be
investigated.
Introduction
Atrophy and fatty infiltration of skeletal muscle are con-
sequences of rotator cuff tendon tears in animal models and
in humans [4, 14, 26]. Muscle atrophy depends on the size
of tear and time elapsed since the tear [13, 26, 34, 42].
Even after structurally successful surgical tendon repair,
skeletal muscles of the rotator cuff only partially recover
from atrophy [13, 33]. Thus, the original force-generating
capacity of the muscle is not restored and muscle function
remains restricted. If atrophy could be prevented or
reversed, the clinical outcome after rotator cuff tendon
repair could be improved.
Skeletal muscle atrophy results from reduced protein
synthesis and/or increased protein degradation [16, 23].
Various signaling proteins, such as transcription factors,
reportedly regulate skeletal muscle atrophy. In the absence of
growth or survival signals, the transcription factor FOXO
localizes to the nucleus (Fig. 1) and activates genes involved
in cell death and cell cycle inhibition [35]. Specifically,
FOXO induces atrogin-1 and MURF1 and thus leads to
muscle atrophy [22, 31]. This signaling orchestrates three
known proteolytic systems working together in muscle atro-
phy, ie, the calcium-dependent calpain system, the lysosomal
protease system (cathepsins), and the ubiquitin-proteasome
system [21]. The ubiquitous calpains (CAPN1 and CAPN2)
are involved in the disassembly of sarcomeric proteins in
atrophy models [20, 28, 41]. Therefore, myofibrillar proteins
become available for ubiquitination, a prerequisite for deg-
radation by proteasomes that are not able to degrade intact
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myofibrils [1]. Different from the ubiquitous calpains, calpain
3 is not involved in the initial proteolytic events [9], and may
play a role in sarcomere maintenance in mature muscle cells
[9]. The conjugation of ubiquitin to proteins in the ubiquitin-
proteasome system is mediated by a series of sequential
reactions conducted by ubiquitin-activating enzymes (E1),
ubiquitin-conjugating enzymes (E2), and ubiquitin-protein
ligases (E3). Proteins ubiquitinated by polyubiquitin chains
are recognized and degraded by the proteasome [21]. If the
protein substrate is monoubiquitinated or diubiquitinated, it is
degraded by the lysosomal pathway [21]. Cathepsins L, B, D,
and H are the major lysosomal proteases [3] and have dif-
ferent substrate specificities [24, 27, 32]. They hydrolyze
various myofibrillar proteins and are involved in skeletal
muscle atrophy [3].
Although several studies explore acute skeletal muscle
atrophy (eg, disuse, spaceflight, immobilization, or dener-
vation [19, 29, 36, 37], the molecular mechanisms of
chronic atrophy after tendon tears are less well understood
[11]. We presume an understanding of the cascade(s) of
cellular processes that lead to muscle atrophy with tendon
damage could lead to focused pharmacologic treatments
(eg, proteolysis inhibitors) reversing the atrophy.
We therefore (1) compared the expression levels of the
selected gene transcripts of patients with defined rotator
cuff defects compared with the respective transcript levels
in the supraspinatus muscle of patients with intact rotator
cuffs and (2) determined whether the expression varied by
cuff size and age.
Materials and Methods
To determine the expression status of genes involved in
protein degradation, we enrolled 59 consecutive patients
undergoing shoulder surgery: 53 patients had various sizes
of tendon tears (Table 1); six patients had an intact rotator
cuff and underwent surgery for other reasons (impingement
syndrome [n = 2], shoulder instability with Bankart lesion
[n = 1], acromioclavicular arthropathy [n = 2], and gle-
nohumeral degenerative disease [n = 1]). To examine the
influence of defect size, we defined three groups of the 53
patients with rotator cuff tendon tears: tears as much as 1
.
3
of the rotator cuff tendons in sagittal diameter (n = 27), as
much as 2
.
3 (n = 13), and full tears (n = 13). Thus, we had
four groups: three with varying size tears and one without
Fig. 1 The three known proteolytic systems with the corresponding
proteins are shown. The black boxes indicate increases (p \ 0.05) and
gray boxes decreases in the transcript level with increasing size of the
rotator cuff tear (Kruskal-Wallis test over all groups). The dotted boxes
indicate a trend for an upregulation (p \ 0.1). FOXO1A = forkhead
box protein O1A; FOXO3A = forkhead box protein O3A; CAP-
NS1 = calpain small subunit 1; CAPN1 = calpain-1 catalytic subunit;
CAPN2 = calpain-2 catalytic subunit; CAPN3 = calpain-3; Ub =
ubiquitin; E1 = ubiquitin-activating enzyme; E2 = ubiquitin-conju-
gating enzyme; UBE2J1 = ubiquitin-conjugating enzyme E2 J1;
UBE2B = ubiquitin-conjugating enzyme E2 B; E3 = ubiquitin-
protein ligase; UBE3A = ubiquitin-protein ligase E3A; MURF1 =
muscle-specific RING finger protein 1; UBE4B = ubiquitin conjuga-
tion factor E4 B; CTSB = cathepsin B; CTSL = cathepsin L.
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tears. The median patient age was 57.3 years (range, 27–
87 years). There was no difference in the distribution of
men and women among the groups without rotator cuff
tendon tears and with different sizes of tendon tears in
sagittal diameter (Table 1). Patients with tendon tears were
on average 20 years older (p \ 0.001) than patients with
intact tendons. The body mass index (median, 25.7 kg/m2)
was not related to the size of the rotator cuff tendon tear.
Our power analysis indicated, to detect a threshold of
differential expression of 2.5, presuming this increase
would influence protein expression and ultimately clini-
cally relevant proteolysis, six patients per group were
required. The study was approved by the institutional
investigational review board. All patients provided signed
informed consent to participate in this study.
We (SS, PS, FR) determined the Constant-Murley score
[7] and Goutallier stages on standardized MRI (parasagittal
T1-weighted turbo spin echo) preoperatively [10, 17].
Goutallier Stage 0 corresponds to a completely normal
muscle, without any fatty streak; Stage 1, the muscle
contains some fatty streaks; Stage 2, fatty infiltration is
important, but there is still more muscle than fat present;
Stage 3, there is as much fat as muscle; and Stage 4, there
is more fat than muscle present [17, 18]. For the 59
patients, the Goutallier stage increased with increasing size
of the rotator cuff tendon tear (p = 0.002), and the
Constant-Murley score also was related to tendon tear size
(p = 0.019), with maximal values observed in Group 1
(Table 1). To measure the extent of atrophy, we (FR, MZ)
determined the muscle cross-sectional area of the supra-
spinatus in the most lateral MR image where the scapular
spine is in contact with the rest of the scapula [34]. This
muscle area was standardized to the area of the supraspi-
natus fossa, which is considered representative for body
constitution [42]. Areas were measured on the MR console
using the manufacturer’s standard software. We found the
muscle cross-sectional area standardized to the area of the
supraspinatus fossa decreased with increasing tear size
(p \ 0.001), indicating ongoing muscle atrophy (Table 1).
Biopsy specimens of the supraspinatus muscle of
approximately 20 mg were collected during surgery (before
repair) and sampled immediately thereafter, which was
described previously [11]. To avoid the influence on gene
expression of muscular inhomogeneity, eg, from different
fiber type composition in different parts of the muscle [2, 25],
biopsy specimens always were taken from the same region of
the muscle, ie, at the anatomic location which corresponds on
MRI to the most lateral part where the scapular spine is in
contact with the rest of the scapula to produce a Y-shaped
appearance as described previously [11, 42].
Total RNA was isolated from 25-lm cryosections of the
biopsy specimens [11, 40]. Specifically, the integrity of
the RNA was analyzed by agarose gel electrophoresis, and
RNA concentrations were estimated with the RiboGreen1
RNA quantification kit (Invitrogen, Carlsbad, CA). The
expression levels of transcripts encoding proteins involved
in muscle atrophy were analyzed by semiquantitative RT-
PCR in triplicate and normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) transcript levels for
all samples as described previously [8, 11]. Briefly, cDNA
was synthesized from individual RNA extracts in triplicate
using the StrataScript1 First Strand cDNA Synthesis kit
(Stratagene, La Jolla, CA) with oligo-dT primers and
750 ng total RNA template in a total volume of 50 lL. The
primer pairs for PCR amplification of selected gene tran-
scripts were designed with the LightCycler1 Probe Design
Software 2.0 (Roche, Rotkreuz, Switzerland) (Table 2). As
quality control for quantification of PCR products in the
linear range of amplification, PCR reactions were per-
formed with 4 lL and 8 lL of the RT reaction containing
cDNA template equivalent to 5 ng and 10 ng total RNA,
respectively, extracted from individual biopsy specimens.
The following conditions revealed amplification within the
linear range for all selected gene transcripts, indicated by
ratios of 2 ± 0.3 between the detected amounts of PCR
product of a distinct gene transcript generated in parallel
reactions with twofold different amounts of template. After
initial denaturation at 94C for 3 minutes, cDNA repre-
senting GAPDH or individual atrophy-related transcripts
were amplified by 25 or 35 PCR cycles (denaturation at
94C for 40 seconds, primer pair-dependent annealing at a
specific temperature [Table 2] for 40 seconds, and elon-
gation at 72C for 20 seconds), respectively. PCR was
completed by a final elongation step at 72C for 7 minutes.
Table 1. Patient characteristics
Rotator
cuff tear
Males/females* Goutallier stage
0/1/2/3/4
Age (years) Constant-Murley
score (%)
Muscle area/
fossa area
Intact tendon 5/1 (6) 3/2/1/0/0 37.8 (26.3–51.5) 56 (42–83) 1.54 (1.11–1.94)
B 1
.
3 18/9 (27) 4/13/7/0/0 55.1 (48.0–57.0) 73 (69–77)§ 1.10 (0.83–1.42)
B 2
.
3 8/5 (13) 0/6/6/0/1 58.0 (53.1–67.0) 58 (20–73) 0.73 (0.49–1.16)
B full 4/9 (13) 0/1/7/2/3 66.9 (54.8–69.2) 49 (16–64) 0.49 (0.40–0.83)
* Values expressed as number of males/females, with the total number of patients in parentheses; values expressed as median, with 95% confidence
interval in parentheses; different from patients without rupture (p \ 0.05); §tends to be different from patients without rupture (p \ 0.1).
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PCR products were analyzed by agarose gel electrophoresis
and quantified with Quantity One1 1D Analysis software
provided by the VersaDocTM Imaging System (Bio-Rad
Laboratories, Hercules, CA) [11].
Data are presented as median and 95% confidence
interval. We used a chi square test to determine whether the
categories of nominal or ordinal scaled data (gender,
Goutallier stage, dominance) were distributed equally
among the four groups. We used a correlation analysis to
determine whether any of the transcripts varied with age.
For the transcripts, the gene expression level of each group
was normalized to the median of the control group. We
determined the differences in transcript levels of the
respective genes of interest with respect to the size of the
rotator cuff tendon tear using the Kruskal-Wallis test. We
determined differences of gene expression between any
two respective groups with differing tear sizes (Table 3)
using the Mann-Whitney U test; we did not use post hoc
tests for multiple comparisons. We used SPSS1 for
Windows1 11.5.0 (SPSS Inc, Chicago, IL).
Table 2. Genes and primer sequences of the analyzed transcripts
Gene name GenBank ID Forward primer (50–30) Annealing temperature (C)
Reverse primer (50–30)
FOXO1A NM_002015 CTTGTATGTTAATTGCATCTTCATTGGCTTGGTA 65
GCTGTGCTTAGAGGAACTTGGGT
FOXO3A NM_001455 TCATGATGACACAGTCGGACCC 64
TGGTGGTGGAGCAAGTTCTGATT
MSTN NM_005259 TGGTAGTAGACCGCTGTGGGTG 64
CTTGTATGATTTGTTTGGATGGTTAAATGCC
CAPNS1 NM_001749 TGAGGCCAACGAGAGTGAGGA 64
CTTGCCTGTGGTGTCGCTAT
CAPN1 NM_005186 GCAAGTGCTCTCAGAAGAGGAGATTGACG 67
CCATTGCCATCACGATCCATGAGGTT
CAPN2 NM_001748 CCCTGTCAACTCCACCAAGTCATCGT 68
AAGTACTGAGAAACAGAGCCAAGAGATAAGGTCG
CAPN3 NM_000070 GCCTCCCAGCGAGTACGTCA 67
GCTCCTTGTTGCTGTTTGCTCTGTCC
UBE2J1 NM_016021 AACAGCCTTCCCTCCGTT 64
AGCAGGTGGCTAGCTGACA
UBE2B NM_003337 ATGAGCAGAGAACTGATGCGACTTGT 67
CCCAGCCTATAAGCATTTATCCAATCAATGT
UBE3A NM_000462 CTATGTCTGTGCCTCCCTTCTTTATTGG 64
AAGGCTCAACCTCAAGCAGTAATAAAC
Atrogin-1 NM_058229 TGCAGCCAAGAAGAGAAAGAAGGACA 66
TCCAACAGCCGGACCACGTAG
MURF1 NM_032588 GGGCTTTGAGAACATGGACTTCTTTACTTTGGATT 68
GGTGTCCTTCTTCCTTCCCTTCTGTGG
UBE4B NM_006048 ATGAAAGTCTGGAGTCTCTGAAGCGAA 66
GGGCGAGGTAAGAGCGGGACA
CTSB BC001908 ACAGGCCATGTGAGCCACCG 68
CGCTTTCCATTCCTGCGTCTCTGTCTTG
CTSL NM_145918 ATGAATCCTACACTCATCCTTGCTGCCTTT 68
CCACACTGCTCTCCTCCATCCTTCTT
GAPDH NM_002046 TGAACGGGAAGCTCACTGGCATGG 67
TGGGTGTCGCTGTTGAAGTCAGAGGAGA
MSTN = myostatin; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; FOXO1A = forkhead box protein O1A; FOXO3A = forkhead
box protein O3A; CAPNS1 = calpain small subunit 1; CAPN1 = calpain-1 catalytic subunit; CAPN2 = calpain-2 catalytic subunit;
CAPN3 = calpain-3; UBE2J1 = ubiquitin-conjugating enzyme E2 J1; UBE2B = ubiquitin-conjugating enzyme E2 B; UBE3A = ubiquitin-
protein ligase E3A; MURF1 = muscle-specific RING finger protein 1; UBE4B = ubiquitin conjugation factor E4 B; CTSB = cathepsin B;
CTSL = cathepsin L.
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Results
Several genes involved in protein degradation were
upregulated at the mRNA level in the muscles of massive
rotator cuff tears (Table 3). However, we identified no
specific degradation pathway where upregulation was
substantially greater than another.
Of the transcription factors analyzed in this analysis,
FOXO1A was upregulated in the muscles of massive
tears compared with smaller tears and controls, whereas
FOXO3A was downregulated if the tear became larger
than 1
.
3 (Table 3). In the calpain group, CAPN1 was
upregulated in massive tears. In the ubiquitin-proteasome
pathway group, UBE2B and UBE3A were upregulated in
the muscles of massive tears compared with smaller
tears and controls. In the lysosomal group, CTSB was
upregulated in massive tears compared with smaller
tears. Of all genes analyzed, CAPN1, UBE2B, and
UBE3A were upregulated greater than twofold in the
muscles of massive tears compared with smaller tears
and controls.
Gene expression of each transcript did not correlate
(r2 \ 0.1) with age (Fig. 2; Table 4). Thus, at most 10%
variation of the expression levels could be explained by age
of the patients.
Discussion
Rotator cuff tears lead to atrophy, fatty infiltration of
skeletal muscles, pain, and loss of shoulder function.
Therefore, massive rotator cuff tears with considerable
atrophy and high muscular fat content of the corresponding
muscles have a poor outcome after surgery. We presume
identification of the molecular mechanisms of chronic
atrophy could lead to pharmacologic treatments (eg,
blocking agents to proteolysis). To recognize indicator
molecules for increased muscle structure degradation
causing atrophy in supraspinatus muscle of patients with
rotator cuff tears, we investigated expression at the tran-
script level of selected genes, which encode proteins
representative of four groups that orchestrate proteolysis.
These include transcription factors and proteins represent-
ing the calpain, lysosomal, and ubiquitin-proteasome
proteolytic pathways.
Owing to limitations of such a study in patients, the
findings need critical discussion. Gene expression can be
influenced by the timing of responses to injury and we did
not know the time that had elapsed between the rotator cuff
tendon tear and surgery. By analyzing patients’ histories,
we estimated the time between tendon tearing until sur-
gery, which ranged from months to years. Therefore, the
Table 3. Results of the RT-PCR analysis
Protein category Gene name p Value Intact tendon B 1
.
3 B 2
.
3 B Full
Transcription factor/signaling FOXO1A* 0.002 1.0 (0.4–1.7) 1.1 (0.7–1.2) 0.8 (0.5–1.4) 1.6 (1.3–2.2)
FOXO3A* 0.008 1.0 (0.3–1.3) 1.0 (0.8–1.1) 0.5 (0.2–0.6) 0.6 (0.2–1.0)
MSTN 0.147 1.0 (0.3–2.1) 1.2 (1.1–1.6) 1.7 (0.9–2.1) 1.9 (0.4–3.1)
Ca2+-dependent calpains CAPNS1 0.051 1.0 (0.5–1.3) 0.9 (0.8–1.0) 1.0 (0.7–1.1) 1.2 (1.0–2.1)
CAPN1 0.071 1.0 (0.5–6.3) 2.2 (1.7–2.9) 2.0 (1.5–4.0) 2.7 (1.9–4.7)
CAPN2 0.118 1.0 (0.8–4.2) 1.4 (1.1–1.9) 1.2 (0.5–1.6) 1.7 (1.1–2.1)
CAPN3* 0.047 1.0 (0.3–1.4) 1.2 (1.0–1.3) 0.8 (0.5–0.9) 1.2 (0.9–1.3)
Ubiquitin- proteasome pathway UBE2J1 0.685 1.0 (0.7–1.3) 1.0 (0.6–1.9) 1.2 (1.1–1.3) ND
UBE2B* 0.006 1.0 (0.4–1.4) 1.2 (1.1–1.9) 1.2 (1.0–1.3) 2.1 (1.2–2.7)
UBE3A* 0.007 1.0 (0.3–7.1) 0.7 (0.5–1.1) 1.9 (0.5–3.0) 3.5 (0.8–6.5)
Atrogin-1 0.195 1.0 (0.7–1.6) 0.8 (0.8–1.0) 1.0 (0.8–1.5) 1.1 (0.8–1.6)
MURF1 0.491 1.0 (0.3–1.1) 0.9 (0.7–1.1) 0.7 (0.6–1.0) 0.8 (0.4–1.0)
UBE4B 0.564 1.0 (0.4–1.2) 0.9 (0.8–1.0) 0.9 (0.5–1.1) 1.1 (0.7–1.4)
Lysosomal enzymes CTSB* 0.015 1.0 (0.3–3.6) 0.9 (0.6–1.5) 0.8 (0.5–1.4) 1.5 (1.0–3.4)
CTSL 0.245 1.0 (0.7–1.4) 0.9 (0.7–1.4) 0.7 (0.5–0.9) 0.9 (0.4–2.5)
Values expressed as median ratio of mRNA levels of patients with different extent of rotator cuff tendon tears to patients with intact tendon, with
95% confidence intervals in parentheses; *transcripts that are altered compared with intact tendon (p \ 0.05; Kruskal-Wallis test over all
groups); p values refer to entire cohort of patients including all four subgroups; different from the group with the next smaller size tendon tear
(p \ 0.05; Mann-Whitney U test comparing two groups); ND = not detected; MSTN = myostatin; FOXO1A = forkhead box protein O1A;
FOXO3A = forkhead box protein O3A; CAPNS1 = calpain small subunit 1; CAPN1 = calpain-1 catalytic subunit; CAPN2 = calpain-2
catalytic subunit; CAPN3 = calpain-3; UBE2J1 = ubiquitin-conjugating enzyme E2 J1; UBE2B = ubiquitin-conjugating enzyme E2 B;
UBE3A = ubiquitin-protein ligase E3A; MURF1 = muscle-specific RING finger protein 1; UBE4B = ubiquitin conjugation factor E4 B;
CTSB = cathepsin B; CTSL = cathepsin L.
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muscle biopsies performed in our study represent only the
chronic phase of atrophy and must be distinguished from
the acute phase. Another potential limitation of our study
was the age difference in the group with intact rotator cuff
versus the other groups with varying sizes of rotator cuff
tendon tears because age may influence gene expression of
proteins involved in skeletal muscle atrophy [6, 15, 39].
We analyzed expression values using the Kruskal-Wallis
test including all four groups together. Additionally, we
compared the expression values of each group with any
extent of tendon tear with the group with intact tendons and
the massive tear group with the next smaller extent of
tendon tear. The latter analysis revealed the main differ-
ences in expression occurred in massive tears compared
with the second largest tear size group. For these two
groups, there was no difference in age. Given less than
10% of the variation in expression levels could be
explained by age, we presume age is not a causative factor.
The significantly upregulated or downregulated gene tran-
scripts we observed indicate altered proteolysis in
supraspinatus muscle of patients with a rotator cuff tear.
However, the findings must be confirmed at the protein
level, and the biological role of these proteins in interaction
with cellular mechanisms that contribute to muscle atrophy
remain to be investigated because expression at the mRNA
level may not correlate with protein expression or biolog-
ical relevance.
To understand and interpret our findings, the temporal
expression patterns of genes must be considered. The
expression level of mRNA encoding proteins involved in
skeletal muscle atrophy varies with time after a tendon tear.
For example, atrogin-1 and MURF1, which represent key
regulators of muscle atrophy, appear only transiently ele-
vated during rapid muscle mass loss in the acute phase of
skeletal muscle atrophy [5, 30]. Therefore, these two genes
showed no changes in expression levels because our
analysis included only chronic tears and mRNA levels
normalized again after the acute phase. The fact that
MURF1 was not upregulated also may reflect the fact that
age may not influence our findings as it is upregulated in
aged skeletal muscles [6, 15, 39]. Also, the expression of
FOXO1A is upregulated in acute tears and persists at an
elevated level [30]. These findings may be consistent with
our increased expression of FOXO1A. The greatest dif-
ferential expression was identified in UBE2B and UBE3A,
which act in concert in the ubiquitination of soluble muscle
proteins and in CAPN1 [38]. We found them upregulated
particularly in massive rotator cuff tears. This may indicate
it is the UBE genes in the ubiquitin-proteasome pathway
and not the atrogin-1 and MURF1 genes which play an
important role in mediating the molecular processes of
atrophy in massive rotator cuff tears. One key player of the
lysosomal pathway, CTSB, also is upregulated. This indi-
cates all gene families involved in protein degradation are
represented in the atrophy process in patients with massive
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Fig. 2A–B Scatterplots of (A)
atrogin-1 and (B) FOXO1A
mRNA levels indicate the
expression of these genes is not
age related.
Table 4. Coefficient of determination of age and gene expression
Gene name R2
FOXO1A 0.095
FOXO3A 0.022
MSTN 0.002
CAPNS1 0.049
CAPN1 0.027
CAPN2 0.012
CAPN3 0.002
UBE2J1 0.021
UBE2B 0.084
UBE3A 0.064
Atrogin-1 0.001
MURF1 0.002
UBE4B 0.010
CTSB 0.083
CTSL 0.029
R2 = coefficient of determination; MSTN = myostatin; FOXO1A =
forkhead box protein O1A; FOXO3A = forkhead box protein O3A;
CAPNS1 = calpain small subunit 1; CAPN1 = calpain-1 catalytic
subunit; CAPN2 = calpain-2 catalytic subunit; CAPN3 = calpain-3;
UBE2J1 = ubiquitin-conjugating enzyme E2 J1; UBE2B = ubiquitin-
conjugating enzyme E2 B; UBE3A = ubiquitin-protein ligase E3A;
MURF1 = muscle-specific RING finger protein 1; UBE4B =
ubiquitin conjugation factor E4 B; CTSB = cathepsin B; CTSL =
cathepsin L.
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rotator cuff tears, suggesting the cellular processes
involved in this atrophy are complex and these pathways
are orchestrated among each other (Fig. 1). However, in
view of this complexity, our analysis represents a pre-
liminary study providing the rationale for in vitro studies
that require more detailed analysis at the protein and
functional levels to better characterize the role of these
genes in the atrophy process of rotator cuff tears.
Our data suggest mRNA levels of atrophy-related genes
were increased preferentially in biopsy specimens from our
patients with large or massive rotator cuff tendon tears.
Massive rotator cuff tears were associated with increased
muscular atrophy and fatty infiltration [13]. Therefore, the
repair of massive tears often is followed by retears of the
tendons and accompanied by additional muscular degen-
eration [13]. Consequently, the outcome after surgical
repair of massive tears is often less satisfactory than out-
come in patients with smaller tears [12]. Considering the
fact that protein degradation genes are overexpressed in the
muscles of massive rotator cuff tears, our results parallel
the clinical observations of increased atrophy and muscular
degeneration in large tears compared with small tears.
Therefore, it may be that the activity of atrophy genes in
muscles of patients with massive rotator cuff tendon tears
may contribute to the unsatisfying results after surgical
repair.
We found the transcript levels of distinct genes involved
in skeletal muscle atrophy increased in patients with mas-
sive rupture of the rotator cuff tendons compared with
patients with smaller tears or without tears. Increased
activity of these genes may contribute to impaired func-
tional recovery of atrophic muscles after surgical rotator
cuff repair. Taken together, the observations suggest
upregulation of the transcripts encoding FOXO1A, cal-
pains, UBE2B, UBE3A, and CTSB, which reflect
molecular events in the rotator cuff muscle after tendon
tears and concomitant muscle atrophy.
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